---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-123305"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:35:11.641062+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NextCure enters ATM agreement for up to $14.5M common stock offering with H.C. Wainwright

## Summary
- ATM agreement allows sale of up to $14.5M of common stock at market prices, effective December 19, 2025.
- Agent H.C. Wainwright receives 3.0% compensation on gross proceeds from shares sold.
- Net proceeds to fund general corporate purposes, including preclinical studies and clinical trials.
- Sales may be made on Nasdaq or in negotiated transactions; no minimum price or volume commitments.

## SEC filing metadata
- accession: 0001104659-25-123305
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465925123305/0001104659-25-123305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465925123305/tm2533962d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-123305
- JSON: https://secwatch.observer/filing/0001104659-25-123305.json
- Plain text: https://secwatch.observer/filing/0001104659-25-123305.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.